Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
Weiss
K
K
Department of Nuclear Medicine, University of Vienna, Austria.
Köck
H H
HH
Atefie
K
K
Sinzinger
H
H
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D012074:Remission Induction; D012493:Samarium / Q000627:therapeutic use*
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D019275:Radiopharmaceuticals; D012493:Samarium; C061972:samarium Sm-153 lexidronam